Infant vitamin B12 status and its predictors - cross-sectional baseline results from an ongoing randomized controlled trial.

What Was Tested

This randomized controlled trial looks at Cyanocobalamin (Vitamin B12).

The objective of this study was to describe vitamin B12 status in Norwegian infants aged 6-15 wk using multiple biomarkers and cut-off approaches, and to identify its predictors.

Why It Was Studied

Vitamin B12 is a crucial micronutrient for infant growth and development.

Who Took Part

The study group was 2024, infants.

The age groups tagged for this paper are infants, both men and women.

From November 2021 through August 2024, infants aged 6-15 wk and their mothers were recruited from public health clinics in Innlandet County, Norway, as part of an ongoing randomized controlled trial.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Cyanocobalamin (Vitamin B12) and who got the comparison, which limits bias.

Plasma cobalamin and methylmalonic acid (MMA) concentrations were analyzed among all infants in the cohort (n = 644), and total homocysteine (tHcy) concentrations were analyzed in a subgroup (n = 358).

The combined indicator for vitamin B12 status (cB12) was calculated by Fedosov's equation.

Low status was defined using multiple cut-off approaches.

Potential predictors of infant vitamin B12 status were evaluated using regression models.

What Was Measured

Topics PubMed links to this paper include Vitamin B 12, Cross-Sectional Studies, Norway, Methylmalonic Acid, Homocysteine, Vitamin B 12 Deficiency and Biomarkers.

The authors tagged it with the keywords Vitamin B12, breastfeeding, cB12, cobalamin, infants and micronutrient.

What This Means in Plain Language

The paper is a randomized study of Cyanocobalamin (Vitamin B12) in 2024, infants.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 13 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (The American journal of clinical nutrition), a journal based in United States.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.